Eagle Asset Management Inc Arvinas, Inc. Transaction History

Eagle Asset Management Inc

  • $16.7 Billion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023
SELL
$21.73 - $31.43 $2.34 Million - $3.38 Million
-107,577 Reduced 85.57%
18,137 $450,000
Q1 2023

May 08, 2023
SELL
$26.15 - $37.26 $3.56 Million - $5.07 Million
-135,978 Reduced 51.96%
125,714 $3.43 Million
Q4 2022

Feb 14, 2023
SELL
$32.47 - $57.24 $373,112 - $657,744
-11,491 Reduced 4.21%
261,692 $8.95 Million
Q3 2022

Nov 07, 2022
SELL
$41.87 - $57.99 $311,805 - $431,851
-7,447 Reduced 2.65%
273,183 $12.2 Million
Q2 2022

Aug 10, 2022
SELL
$36.01 - $74.24 $932,154 - $1.92 Million
-25,886 Reduced 8.45%
280,630 $11.8 Million
Q1 2022

May 12, 2022
BUY
$60.27 - $81.57 $838,958 - $1.14 Million
13,920 Added 4.76%
306,516 $20.6 Million
Q4 2021

Feb 11, 2022
SELL
$65.85 - $96.21 $253,588 - $370,504
-3,851 Reduced 1.3%
292,596 $23.4 Million
Q3 2021

Nov 10, 2021
SELL
$73.2 - $107.87 $4.07 Million - $5.99 Million
-55,575 Reduced 15.79%
296,447 $24.4 Million
Q2 2021

Aug 11, 2021
SELL
$60.45 - $84.26 $222,758 - $310,498
-3,685 Reduced 1.04%
352,022 $27.1 Million
Q1 2021

May 14, 2021
BUY
$58.19 - $91.37 $1.29 Million - $2.03 Million
22,210 Added 6.66%
355,707 $23.4 Million
Q4 2020

Feb 12, 2021
BUY
$20.19 - $84.93 $6.73 Million - $28.3 Million
333,497 New
333,497 $28.3 Million

Others Institutions Holding ARVN

# of Institutions
224
Shares Held
70.9M
Call Options Held
1.52M
Put Options Held
346K
View Full List

About ARVINAS, INC.

ARVN Quotes by TradingView
  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $986M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Eagle Asset Management Inc Portfolio

Follow Eagle Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email